Study and Computational Modeling of Fatty Acid Effects on Drug Solubility in Lipid-Based Systems.


Journal

Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R

Informations de publication

Date de publication:
06 2022
Historique:
received: 31 05 2021
revised: 25 11 2021
accepted: 26 11 2021
pubmed: 6 12 2021
medline: 25 5 2022
entrez: 5 12 2021
Statut: ppublish

Résumé

Lipid-based systems have many advantages in formulation of poorly water-soluble drugs but issues of a limited solvent capacity are often encountered in development. One of the possible solubilization approaches of especially basic drugs could be the addition of fatty acids to oils but currently, a systematic study is lacking. Therefore, the present work investigated apparently neutral and basic drugs in medium chain triglycerides (MCT) alone and with added either caproic acid (C6), caprylic acid (C8), capric acid (C10) or oleic acid (C18:1) at different levels (5 - 20%, w/w). A miniaturized solubility assay was used together with X-ray diffraction to analyze the residual solid and finally, solubility data were modeled using the conductor-like screening model for real solvents (COSMO-RS). Some drug bases had an MCT solubility of only a few mg/ml or less but addition of fatty acids provided in some formulations exceptional drug loading of up to about 20% (w/w). The solubility changes were in general more pronounced the shorter the chain length was and the longest oleic acid even displayed a negative effect in mixtures of celecoxib and fenofibrate. The COSMO-RS prediction accuracy was highly specific for the given compounds with root mean square errors (RMSE) ranging from an excellent 0.07 to a highest value of 1.12. The latter was obtained with the strongest model base pimozide for which a new solid form was found in some samples. In conclusion, targeting specific molecular interactions with the solute combined with mechanistic modeling provides new tools to advance lipid-based drug delivery.

Identifiants

pubmed: 34863971
pii: S0022-3549(21)00642-0
doi: 10.1016/j.xphs.2021.11.023
pii:
doi:

Substances chimiques

Fatty Acids 0
Oleic Acids 0
Pharmaceutical Preparations 0
Solvents 0
Triglycerides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1728-1738

Informations de copyright

Copyright © 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Nicole Wyttenbach (N)

F. Hoffmann-La Roche Ltd., Pharmaceutical Research & Early Development, Roche Innovation Center Basel, Grenzacherstr. 124, CH- 4070 Basel, Switzerland.

Andreas Niederquell (A)

University of Applied Sciences and Arts Northwest. Switzerland, Institute of Pharma Technology Hofackerstr. 30, CH- 4132 Muttenz, Switzerland.

Philipp Ectors (P)

F. Hoffmann-La Roche Ltd., Pharma Technical Development, Grenzacherstr. 124, CH-4070 Basel, Switzerland.

Martin Kuentz (M)

University of Applied Sciences and Arts Northwest. Switzerland, Institute of Pharma Technology Hofackerstr. 30, CH- 4132 Muttenz, Switzerland. Electronic address: martin.kuentz@fhnw.ch.

Articles similaires

Humans Pharmaceutical Preparations Drug Utilization Prescription Drugs
Humans Meta-Analysis as Topic Sample Size Models, Statistical Computer Simulation
Humans Algorithms Software Artificial Intelligence Computer Simulation
Humans Robotic Surgical Procedures Clinical Competence Male Female

Classifications MeSH